Lataa...
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
BACKGROUND: There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime–boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes wou...
Tallennettuna:
| Julkaisussa: | PLoS Med |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Library of Science
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6490884/ https://ncbi.nlm.nih.gov/pubmed/31039172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002790 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|